Inspired by nature. Nourished by science.
At Virentia, we believe that science can unleash the power of plants
Founded in 2016, Virentia is a biotech company based in Québec, Canada, that specializes in the development and production of value-added compounds obtained through a refined fractionation process of plant aerial biomass. These compounds are then commercialized as nutraceuticals, specialized ingredients for human, and active ingredients crop protection.
Virentia’s vision is to create a thriving ecosystem of growers, research partners, distributors and manufacturers that work together to advance plant science and offer consumers premium products that promote health and well-being.
Our mission is to develop innovative plant compounds that can be leveraged to create high-quality, eco-responsible and natural foods for human nutrition.
We are one team.
Our innovations deliver results.
Science governs everything we do.
We are a socially and environmentally responsible company.
Guillaume has over 20 years of management and business leadership experience related to strategic vision, operations, financing and administration. Involved in different start-up in green technologies and life science , he experienced all phases of development of a projet from the beginning to the implementation of the industrial process. Previously Executive Vice-President and Chief Financial Officer at Groupe BPR, Guillaume contributed to the engineering services company’s expansion, which, in the space of seven years, increased its revenues from $85 million to more than $225 million to be subsequently integrated into the Tetra Tech group. He also serves as a Boards member of various privately held companies in the fields of technology, consumer goods and real estate. Guillaume obtained a Master’s degree in Business Administration with a specialization in Finance from the Université de Sherbrooke as well as a Bachelor’s degree in Health Science (Medicine) from Université Laval. He also is a Chartered Financial Analyst (CFA) charterholder.
Dr. Vézina has an academic background in plant molecular biology and biotechnology, with over 300 patents issued and 70 scientific publications written to his name. Throughout his career, he contributed to significant scientific and technical advances in the fields of biotechnology, vaccine development and large-scale processing, where he was awarded various prizes and awards, and specifically for his contribution to the development of the biotechnology and biopharmaceutical industries Canada. He is also a much-sought-after speaker at internationally renowned conferences, including these organized by BIO, WHO, Institut Pasteur, NIH, IVI, PATH, DARPA, BARDA and CBMS.
Prior to his tenure at Virentia, Dr. Vézina was the Co-founder and Chief Scientific Officer and Scientific Director MEDICAGO, a biotech company acquired in 2013 by Philip Morris and Mitsubishi Tanabe Pharma. In this role, he carried out the development and authorship of several patents related to the processing and production of a new generation of vaccines. Before the acquisition, MEDICAGO was one of the best technological and financial successes in Canadian biopharmaceutical history and garnered acclaim for its “Best New Technology/ Vaccine production platform” from the World Vaccine Organization.The Vaccine Industry Excellence (VIE) Awards recognize the outstanding achievements of scientists and vaccine industry stakeholders in the global vaccine industry.
Pierre Lavallée, Chemist, Ph.D.
Vice-President, Principal and Project Leader
Dr. Lavallée has over 30 years of experience in environmental, industrial sanitation (petrochemical, metallurgy and pulp and paper) and urban hydraulics. He has extensive expertise in brownfield and greenfield projects for major organizations across North America and Europe. For the past 10 years, he has worked in research and development for energetic processes, agrifood technology and biotechnology.
He began his career with I&C in real-time process control at the Ph.D. level. He later progressed to management positions and was the head of a large engineering consulting firm of 2 000 employees
Dr. Lavallée has always remained involved in R&D and emerging technologies development, specifically in the environmental fields and natural resources preservation and protection. He is an esteemed author of nearly a hundred scientific and technical documents.
Christopher Lainesse, B.B.A
Executive Vice-President & General Manager
Mr. Lainesse has over two decades of experience in business development, sales and marketing for major international organizations, including Shell and Groupe Touchette, the largest Canadian-owned tire distributor in Canada.
Prior to Virentia, Mr. Lainesse was Vice-President of Sales at Premier Tech, a leading Canadian manufacturing group specializing in horticulture and agriculture, industrial equipment, and environmental technologies.
During his tenures, he played an instrumental role in growing the market share of the companies he worked for across multiple key markets, including North and South America, APAC and China. He also has a proven track record in sales turnarounds and optimal sales force development.
Audrey Lavoie, MBA, D.E.S.S.
Vice President, Human Resources and Marketing
Audrey has an impressive and diversified track record in human resources, marketing and finance with financial institutions like Desjardins Wealth Management, National Bank and Scotiabank. In addition to having worked for SMEs in England and the United States, she taught at the Université du Québec à Chicoutimi.
She has a keen interest in innovative business practices, and Virentia benefits from her wealth of experience. Audrey’s everyday commitment is to mobilize team members and reach high standards of quality.
Let’s talk about alfalfa-based innovation